Daratumumab in STK11 Mutated NSCLC

Clinical trial NCT05807048 · COMPLETED

Trial details

NCT number: NCT05807048
Sponsor: NYU Langone Health
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Start date: 2023-06-01
Primary completion: 2025-11-11
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.